A detailed history of Banco Bilbao Vizcaya Argentaria, S.A. transactions in Novavax Inc stock. As of the latest transaction made, Banco Bilbao Vizcaya Argentaria, S.A. holds 77,607 shares of NVAX stock, worth $625,512. This represents 0.01% of its overall portfolio holdings.

Number of Shares
77,607
Holding current value
$625,512
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.71 - $17.11 $831,170 - $1.33 Million
77,607 New
77,607 $980,000
Q2 2024

Aug 06, 2024

SELL
$3.89 - $20.97 $32,535 - $175,393
-8,364 Reduced 9.62%
78,572 $994,000
Q1 2024

May 13, 2024

SELL
$3.76 - $6.02 $19,176 - $30,701
-5,100 Reduced 5.54%
86,936 $415,000
Q4 2023

Feb 13, 2024

SELL
$4.8 - $7.67 $43,137 - $68,930
-8,987 Reduced 8.9%
92,036 $441,000
Q3 2023

Nov 08, 2023

SELL
$6.81 - $9.74 $194,725 - $278,505
-28,594 Reduced 22.06%
101,023 $731,000
Q2 2023

Aug 04, 2023

BUY
$6.67 - $9.52 $28,907 - $41,259
4,334 Added 3.46%
129,617 $963,000
Q1 2023

May 09, 2023

BUY
$5.76 - $12.48 $72,967 - $158,096
12,668 Added 11.25%
125,283 $868,000
Q4 2022

Feb 13, 2023

BUY
$8.86 - $25.04 $53,284 - $150,590
6,014 Added 5.64%
112,615 $1.16 Million
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $695,840 - $2.91 Million
38,233 Added 55.92%
106,601 $2.02 Million
Q2 2022

Aug 08, 2022

BUY
$36.28 - $75.29 $574,348 - $1.19 Million
15,831 Added 30.13%
68,368 $3.55 Million
Q1 2022

May 12, 2022

BUY
$69.73 - $142.9 $3.1 Million - $6.36 Million
44,491 Added 552.96%
52,537 $3.9 Million
Q4 2021

Feb 15, 2022

SELL
$134.56 - $217.97 $2,691 - $4,359
-20 Reduced 0.25%
8,046 $1.22 Million
Q3 2021

Nov 12, 2021

BUY
$177.8 - $270.58 $925,449 - $1.41 Million
5,205 Added 181.93%
8,066 $1.67 Million
Q2 2021

Aug 06, 2021

BUY
$121.0 - $257.67 $346,181 - $737,193
2,861 New
2,861 $612,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $630M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Banco Bilbao Vizcaya Argentaria, S.A. Portfolio

Follow Banco Bilbao Vizcaya Argentaria, S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banco Bilbao Vizcaya Argentaria, S.A., based on Form 13F filings with the SEC.

News

Stay updated on Banco Bilbao Vizcaya Argentaria, S.A. with notifications on news.